尤瑞克林治疗急性脑梗死的近期疗效观察

目的 观察尤瑞克林治疗急性脑梗死的近期疗效。方法 将符合急性脑梗死诊断标准的90例患者，随机分为尤瑞克林治疗组和对照组各45例。两组均给予基础治疗，治疗组同时给予0.15PNA单位尤瑞克林静脉滴注，每日1次，连用14d，比较两组治疗前后美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale，NIHSS），日常生活活动能力（Activities of daily living，ADL）差异。结果 治疗前两组NI HSS和AD L评分无明显差异，治疗后治疗组NI HSS低于对照组，差异有统计学意义（5.6±3.93 vs 7.71±4.01，P =0.004）；治疗后治疗组ADL高于对照组，差异有统计学意义（67.18±37.05 vs 54.23±30.25，P =0.015）。结论 急性脑梗死患者经尤瑞克林治疗后临床症状改善优于对照组，尤瑞克林对治疗急性脑梗死有效 。

Effect of Urinary Kallidinogenase on Acute Cerebral Infarction

Objective To investigate the effect of Urinary Kallidinogenase on acute cerebral infarction. Methods Ninety patients with acute cerebral infarction were randomly divided into two groups： treatment group with Urinary Kallidinogenase and control group. According to Chinese Guidelines for Prevention and Management Cerebrovascular Disease, two groups were treated with basic therapy; treatment group was administrated intravenous injection of Urinary Kallidinogenase 0.15PNAU per day for 14 days. The primary efficacy was evaluated by NIHSS（the National Institutes of Health stroke scale, NIHSS）, ADL（Activities of daily living, ADL）. Results Acute cerebral infarction patients after treatment by Urinary Kallidinogenase clinical symptoms improved than control group, NIHSS（5.6±3.93 vs 7.71±4.01, P=0.004）, ADL（67.18±37.05 vs 54.23±30.25, P=0.015）. Conclusion Urinary Kallidinogenase can be effectively treated acute cerebral infarction.